🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06471400
Recruiting Not applicable

Developing Strategies to Facilitate Consent of Legally Authorized Representatives to Clinical Trials

NCT06471400 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2024-06-18
Last updated
2024-06-24

Condition(s) studied

Critical IllnessLoss of Consciousness

Investigational drug(s) / intervention(s)

interview

interview: patient relatives or legal authorized representatives will be interviewed

Study summary

This study aims to gather insights into the perceptions of legal representatives regarding the recruitment process for clinical trials in the intensive care setting when the patients cannot decide for themselves. With this information, effective strategies will be developed to increase involvement and the feeling of ownership of LARs of (potential) participants in clinical trials and thus enhance and facilitate patient recruitment for clinical trials. The single-arm study design does not include a choice of comparator, as the focus of this trial is to explore the perceptions of the participants at first hand without comparing different cohorts or strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The study will include LARs of adult patients aged 18 years or older who are admitted to the Freiburg University Medical Center in Germany. Exclusion Criteria: * LARs who have expressed their unwillingness to participate in the study or have objected to the measures implemented in the study will not be included.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Freiburg University Medical Center Freiburg im Breisgau Germany Recruiting

More University Hospital Freiburg trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06471400 on ClinicalTrials.gov ↗ ← All trials in Germany